You are browsing articles on the topic of Heart Failure Archives - CardioExchange

Avatar of Larry Husten, PHD

European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)

News

Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Encouraging Results for Two New Drugs for Hyperkalemia (21 Nov 2014)

News

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. In a phase 3 study, published online in the New England Journal of Medicine, researchers first randomized…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Encouraging Results For Two New Drugs For Hyperkalemia (21 Nov 2014)

News

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.  

Avatar of Tariq

A “Big Data” Approach to Phenotype-Based Clustering of Heart Failure Patients (3 Nov 2014)

Voices

Tariq Ahmad, MD, MPH

Tariq Ahmad discusses his research group’s study of clinical phenotypes in patients with chronic systolic heart failure.

Avatar of Behnood Bikdeli, M.D.

Heart Failure Readmissions: Neighborhood Factors Matter, Too (13 Oct 2014)

Voices

Behnood Bikdeli, M.D.

For two decades, investigators have been studying the association between neighborhood characteristics and cardiovascular disease. A landmark study from 2001 showed that living in a socioeconomically disadvantaged neighborhood was associated with higher incidence of coronary artery disease. Several studies have also shown an association between neighborhood characteristics, most notably the socioeconomic status (SES) and outcomes…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Clyde Yancy, MD

The Implications of PARADIGM-HF for Clinical Practice (29 Sep 2014)

Voices

Clyde Yancy, MD and Mary Norine Walsh, MD

Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.

Avatar of Benjamin Scirica, MD MPH

New Observations on Saxagliptin (15 Sep 2014)

Voices

Benjamin Scirica, MD MPH

Benjamin Scirica discusses his study group’s new analysis of data from the SAVOR-TIMI 53 randomized, placebo-controlled trial of saxagliptin in patients with type 2 diabetes.

Avatar of Boback

Race and Ethnicity Do Not Affect the Benefits of Device Therapy in Heart Failure (11 Sep 2014)

Voices

Boback Ziaeian, MD

Boback Ziaeian discusses his observational study exploring the benefits of guideline-recommended cardiac resynchronization therapy and ICD therapy in heart failure patients, according to race and ethnicity.

Avatar of CardioExchange Editors, Staff

Perspectives on PARADIGM-HF (5 Sep 2014)

Voices

CardioExchange Editors, Staff

The Editors present a distillation of reader comments on a popular post.

Avatar of Vinay

Let’s Take a Close Look at PARADIGM-HF (1 Sep 2014)

Voices

Vinay Prasad, MD MPH

Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.